Occurrence of nodular lymphocyte-predominant Hodgkin lymphoma in Hermansky-Pudlak type 2 syndrome is associated to natural killer and natural killer T cell defects

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Lorenzi, Luisa ^a   Tabellini, Giovanna ^a   Vermi, William ^a,b   Moratto, Daniele ^a   Porta, Fulvio ^c   Notarangelo, Lucia D ^c   Patrizi, Ornella ^a   Sozzani, Silvano ^a   Basile, Genevieve De Saint ^d,e   Latour, Sylvain ^d,e   Pace, David ^f   Lonardi, Silvia ^a   Facchetti, Fabio ^a   Badolato, Raffaele ^a   Parolini, Silvia ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SPEDALI CIVILI   (Italy)

^d INSERM   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f MATER DEI HOSPITAL   (Malta)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD63 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PERFORIN;

ANIMAL CELL; ARTICLE; CASE REPORT; CD8+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; INTERFERON PRODUCTION; LYMPH NODE BIOPSY; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NATURAL KILLER T CELL; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NONHUMAN; OCULAR ALBINISM; PRESCHOOL CHILD; SCHOOL CHILD; SIBLING; TUMOR CELL;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD56; ANTIGENS, CD63; BIOPSY; CHILD; CHILD, PRESCHOOL; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HERMANSKI-PUDLAK SYNDROME; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LYMPH NODES; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; MIDDLE AGED; NATURAL KILLER T-CELLS; PHENOTYPE; SIBLINGS; YOUNG ADULT;

EID: 84896721132     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080131     Document Type: Article

References (48)

1. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
2. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29: 235-271.
3. Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Invest 117: 1137-1146. (Pubitemid 46718398)
4. Tran H, Nourse J, Hall S, Green M, Griffiths L, et al. (2008) Immunodeficiency-associated lymphomas. Blood Rev 22: 261-281.
5. Said JW (2007) Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol 14: 189-194.
6. Elenitoba-Johnson KS, Jaffe ES (1997) Lymphoproliferative disorders associated with congenital immunodeficiencies. Semin Diagn Pathol 14: 35-47. (Pubitemid 27078884)
7. Van den Berg A, Maggio E, Diepstra A, de Jong D, van Krieken J, et al. (2002) Germline FAS gene mutation in a case of ALPS and NLP Hodgkin lymphoma. Blood 99: 1492-1494. (Pubitemid 34547112)
8. Poppema S, Maggio E, van den Berg A (2004) Development of lymphoma in Autoimmune Lymphoproliferative Syndrome (ALPS) and its relationship to Fas gene mutations. Leuk Lymphoma 45: 423-431. (Pubitemid 38196023)
9. Wenham M, Grieve S, Cummins M, Jones ML, Booth S, et al. (2010) Two patients with Hermansky Pudlak syndrome type 2 and novel mutations in AP3B1. Haematologica 95: 333-337.
10. Shotelersuk V, Dell'Angelica EC, Hartnell L, Bonifacino JS, Gahl WA (2000) A new variant of Hermansky-Pudlak syndrome due to mutations in a gene responsible for vesicle formation. Am J Med 108: 423-427. (Pubitemid 30162963)
11. Benson KF, Li FQ, Person RE, Albani D, Duan Z, et al. (2003) Mutations associated with neutropenia in dogs and humans disrupt intracellular transport of neutrophil elastase. NatGenet 35: 90-96. (Pubitemid 37048601)
12. Fontana S, Parolini S, Vermi W, Booth S, Gallo F, et al. (2006) Innate immunity defects in Hermansky-Pudlak type 2 syndrome. Blood 107: 4857-4864. (Pubitemid 43882638)
13. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L (2008) NK cells at the interface between innate and adaptive immunity. Cell Death Differ 15: 226-233.
14. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG (2000) NKT cells: facts, functions and fallacies. Immunol Today 21: 573-583.
15. Berzins SP, Smyth MJ, Baxter AG (2011) Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 11: 131-142.
16. Vermi W, Lonardi S, Morassi M, Rossini C, Tardanico R, et al. (2009) Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. Immunobiology 214: 877-886.
17. Vitale C, Chiossone L, Morreale G, Lanino E, Cottalasso F, et al. (2004) Analysis of the activating receptors and cytolytic function of human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation. Eur J Immunol 34: 455-460. (Pubitemid 39255956)
18. Mingari MC, Poggi A, Biassoni R, Bellomo R, Ciccone E, et al. (1991) In vitro proliferation and cloning of CD3- CD16+ cells from human thymocyte precursors. J Exp Med 174: 21-26.
19. Moretta A, Tambussi G, Bottino C, Tripodi G, Merli A, et al. (1990) A novel surface antigen expressed by a subset of human CD3- CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function. J Exp Med 171: 695-714. (Pubitemid 20088976)
20. Li TK, Houghton PJ, Desai SD, Daroui P, Liu AA, et al. (2003) Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res 63: 8400-8407. (Pubitemid 37549495)
21. Knebel FH, Albuquerque RC, Massaro RR, Maria-Engler SS, Campa A (2013) Dual effect of serum amyloid A on the invasiveness of glioma cells. Mediators Inflamm 2013: 509089.
22. Boaru DA, Dragoş N, Schirmer K (2006) Microcystin-LR induced cellular effects in mammalian and fish primary hepatocyte cultures and cell lines: a comparative study. Toxicology 218: 134-148. (Pubitemid 41821345)
23. Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, et al. (2001) Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31: 1076-1086.
24. Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L (2000) Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 21: 228-234. (Pubitemid 30259028)
25. Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, et al. (2000) X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 192: 337-346. (Pubitemid 30629159)
26. Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, et al. (2010) Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 116: 3853-3864.
27. Moretta L (2010) Dissecting CD56dim human NK cells. Blood 116: 3689-3691.
28. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, et al. (2010) CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116: 3865-3874.
29. Romagnani C, Juelke K, Falco M, Morandi B, D'Agostino A, et al. (2007) CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol 178: 4947-4955. (Pubitemid 46595277)
30. Enders A, Zieger B, Schwarz K, Yoshimi A, Speckmann C, et al. (2006) Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 108: 81-87. (Pubitemid 43990615)
31. Clark RH, Stinchcombe JC, Day A, Blott E, Booth S, et al. (2003) Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat Immunol 4: 1111-1120. (Pubitemid 37428039)
32. Notarangelo L, Casanova JL, Conley ME, Chapel H, Fischer A, et al. (2006) Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol 117: 883-896.
33. Van Krieken JH (2004) Lymphoproliferative disease associated with immune deficiency in children. Am J Clin Pathol 122 Suppl: S122-127.
34. Bauduer F, Vassallo J, Delsol G, Brousset P (2005) Clustering and anticipation for nodular lymphocyte predominance Hodgkin lymphoma within a French Basque kindred. Br J Haematol 130: 648-649. (Pubitemid 43899772)
35. Campbell GN, Lloyd J, Wotherspoon A, Coulter C, Bain BJ (2004) Nodular lymphocyte predominant Hodgkin lymphoma in siblings. Leuk Lymphoma 45: 609-611. (Pubitemid 38196047)
36. Unal A, Sari I, Deniz K, Ozkan M, Kontas O, et al. (2005) Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab. Leuk Lymphoma 46: 1613-1617. (Pubitemid 41700995)
37. Saarinen S, Vahteristo P, Launonen V, Franssila K, Kivirikko S, et al. (2011)Analysis of KLHDC8B in familial nodular lymphocyte predominant Hodgkin lymphoma. Br J Haematol 154: 413-415.
38. Marcenaro E, Carlomagno S, Pesce S, Della Chiesa M, Parolini S, et al. (2011) NK cells and their receptors during viral infections. Immunotherapy 3: 1075-1086.
39. De Maria A, Bozzano F, Cantoni C, Moretta L (2011) Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A 108: 728-732.
40. Pachlopnik Schmid J, Ho CH, Chrétien F, Lefebvre JM, Pivert G, et al. (2009) Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med 1: 112-124.
41. Sasada T, Suekane S (2011) Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. Immunotherapy 3: 1235-1251.
42. Elewaut D, Lawton AP, Nagarajan NA, Maverakis E, Khurana A, et al. (2003) The adaptor protein AP-3 is required for CD1d-mediated antigen presentation of glycosphingolipids and development of Valpha14i NKT cells. J Exp Med 198: 1133-1146. (Pubitemid 37323379)
43. Azakami K, Sato T, Araya N, Utsunomiya A, Kubota R, et al. (2009) Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood 114: 3208-3215.
44. Pachlopnik Schmid J, Canioni D, Moshous D, Touzot F, Mahlaoui N, et al. (2011) Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 117: 1522-1529.
45. Purtilo DT, Sakamoto K, Barnabei V, Seeley J, Bechtold T, et al. (1982) Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): update on studies of the registry. Am J Med 73: 49-56. (Pubitemid 12048276)
46. Xu C, de Vries R, Visser L, Diepstra A, Gadola SD, et al. (2010) Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphoma. Am J Hematol 85: 539-541.
47. Zheng Z, Venkatapathy S, Rao G, Harrington CA (2002) Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells. Leukemia 16: 2429-2437. (Pubitemid 36054378)
48. Fais F, Morabito F, Stelitano C, Callea V, Zanardi S, et al. (2004) CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer 109: 402-411. (Pubitemid 38252769)